Companies

Teva moves US court against Aurobindo Pharma on cancer drug Bendeka

PTI | Updated on May 14, 2020 Published on May 14, 2020

Teva Pharmaceuticals, along with Cephalon Inc and Eagle Pharmaceuticals, has filed a petition in a US court against Aurobindo Pharma alleging that the Indian drug-maker is planning to come out with a generic version of Bendeka, a cancer medicine, before expiration of its patents.

Bendeka (bendamustine hydrochloride) is indicated for chronic lymphocytic leukaemia and indolent B-cell non-Hodgkin lymphoma.

Eagle, the patent-holder, has provided licence to Cephalon the right to sue for infringement of the drug and in 2015, Cephalon assigned its rights to Teva Pharmaceuticals.

Teva filed a probable patent infringement petition on May 11 against Aurobindo in the US district court for the District of Delaware on 28 counts.

On April 6, Aurobindo Pharma had sent a letter (notice letter) to Teva saying that it had submitted US FDA an Abbreviated New Drug Application (ANDA) with paragraph IV certifications to make copycat version before expatriation of the patents of Bendeka Injection, 100 mg/4 mL (25 mg/mL), the petition said.

Teva sought the court a permanent injunction pursuant to, among other things, enjoining Aurobindo, its officers, agents, servants, employees and attorneys, and all persons acting in concert with them, from making, using, selling, offering for sale, marketing, distributing, or importing Aurobindos ANDA product which allegedly infringes the patents-in-suit.

Various patents of bendamustine expire through 2033.

Under Paragraph IV PatentCertifications, a company can seek FDA approval to market a generic drug before the expiration of patents related to the branded medicine that the generic seeks to copy.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on May 14, 2020
This article is closed for comments.
Please Email the Editor